Navigation Links
Bavarian Nordic Publishes its Annual Results 2008
Date:3/27/2009

contract. In 2009 we will have a continued strong focus on fulfilling this contract as well as a strong focus on preparing for the Phase III studies that we expect to initiate with both IMVAMUNE(R) and PROSTVAC(TM) in 2010."

Strong foundation for future growth and earnings

Despite the financial crisis and an economic slowdown, Bavarian Nordic recorded a positive development in 2008, and has laid a strong foundation for further value creation in 2009 and the years ahead. The expected positive development is based on the following elements:

    - Two vaccines moving into Phase III trials

    - Strong financial position

    - Profitable ongoing development and procurement contracts with a value
      of more than DKK 3.5 billion

    - Expectations to the US government's exercise of the contract option for
      additional development and procurement, worth more than DKK 6 billion

    - Ongoing contracts with countries outside USA

    - Partnership with the NCI, a world leading cancer research organisation

    - Strong patent portfolio

    - Pipeline with promising results

    - Future licensing agreement for PROSTVAC(TM)

    - The world's only manufacturing facility dedicated to the
      commercial-scale production of MVA based vaccines

    Important events after the balance sheet date
    IMVAMUNE(R) - end-of-Phase II meeting held with the FDA

After concluding the Phase II development of IMVAMUNE(R), Bavarian Nordic held an end-of-Phase-II meeting with the US health authorities (FDA) in the beginning of 2009 in order to discuss the Phase III study design. The meeting was a success and there was an open and highly constructive discussion with the FDA. Based on the meeting, Phase III studies are expected to be initiated in 2010.

The outcome of the meeting has no impact on the delivery of vaccines to the Strategic National Stockpile (SNS) under the RFP-
'/>"/>

SOURCE Bavarian Nordic A/S
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Bavarian Nordic Receives $50 Million Advance Payment from HHS for Fulfilling Contract Milestones
2. Bavarian Nordic Update - 2007 Annual Results, IMVAMUNE(R) Delivery Contract, Strategy Process
3. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
4. Bavarian Nordic Receives USD 25 Million Milestone Payment After Submission of Important IMVAMUNE(R) Data to The U.S. Health Authorities
5. Bavarian Nordics Case Against Oxford BioMedica
6. Bavarian Nordic Has Essentially Agreed a Pathway for the Licensure of IMVAMUNE(R) With the FDA After Successful End of Phase II Meeting
7. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
8. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
9. Consortium publishes Phase II map of human genetic variation
10. The Lancet Publishes Vasogens ACCLAIM Results
11. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...Intarcia Therapeutics, Inc. delivered two presenta...s delivery of exenatide) program for the treatment...echnology Meeting in San Francisco, CA: ,, (Log...FTU126LOGO ) ,, Continuous Subcutaneous Deliv...e, HbA1c and Reduces Weight in a 28-day Phase 1b S...
(Date:11/5/2009)...rstCall/ -- GenVec, Inc. (Nasdaq: GNVC ) today an...r ended September 30, 2009. GenVec reported a net ...ee months ended September 30, 2009 compared to a n...omparable quarter of 2008. For the nine months end... million ($0.15 per share), compared to a net loss...
(Date:11/5/2009)... -- Imagenetix, Inc. (OTC Bulletin Board: IAGX), a... CEO of Imagenetix, will be presenting the Company...Thursday, December 3rd, at 10:30 AM PST at the Lux..., LD MICRO is a by-invitation only newsletter firm...the micro-cap space. Since 2002, the firm has publ...
(Date:11/5/2009)...l/ -- Transgenomic, Inc. (OTC Bulletin Board: TBIO...r ended September 30, 2009. The Company,s financia... ,, Third Quarter 2009 ,, The Company repo... the third quarter of 2009 as compared to a net lo...arter of 2008. ,, Net sales were $5.0 million ...
Breaking Biology Technology:Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Transgenomic, Inc. Reports Third Quarter 2009 Results 2Transgenomic, Inc. Reports Third Quarter 2009 Results 3Transgenomic, Inc. Reports Third Quarter 2009 Results 4Transgenomic, Inc. Reports Third Quarter 2009 Results 5Transgenomic, Inc. Reports Third Quarter 2009 Results 6Transgenomic, Inc. Reports Third Quarter 2009 Results 7
...by EBS is without merit and part of its overall st...iness without getting shareholder, approval and t...nding to PSC., -...o pursue its business, strategy of obtaining FDA a... and seeking additional federal and third party...
...evenues increased 38% to $42.3 million Full...n, SHANGHAI, China, July 10 /Xinhua-PRNewswire-Fi...d: CHBT) ("China-Biotics", "the,Company"), a leadi...search, development, marketing and distribution of... results for the fourth quarter and fiscal,year en...
...nce, July 10 , - 1st Half-Year Sales Up 16%, - ...reater than or equal,to)12%, EUR millions .../07 EURM %Sales EURM %S... change chang... 13 26.8 71 15 Other EU countries (2) ...
Other Biology Technology:Protein Sciences Responds to Emergent BioSolutions Lawsuit 2Protein Sciences Responds to Emergent BioSolutions Lawsuit 3Protein Sciences Responds to Emergent BioSolutions Lawsuit 4Protein Sciences Responds to Emergent BioSolutions Lawsuit 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2008 Financial Results 13Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth 2
(Date:11/4/2009)...dhood obesity in the United States is reaching epi...vertising on daytime and prime time television dev...ns about the role television plays in obesity, a s...l of Nutrition Education and Behavior examines ho...rge contributor to the problem. , Researchers at...
(Date:11/4/2009)...has received more than $10 million in research gra...ral stimulus program, bringing thetotal amount of ... million. Thirty-three projects achieved stimulus...eather. , "The university has thoughtfully under...holarly excellence to federal agency priorities. ...
(Date:11/4/2009)...Newswire/ -- DigitalPersona, Inc., a leader in fin...day announced that WAND Corporation, a leading sup...rvice restaurants, has integrated DigitalPersona t...olutions. WAND,s quick-service customers can now u...ability and deter unauthorized manager overrides. ...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 2OU achieves $10 million in stimulus grants for 33 projects on the Norman campus 3WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 2WAND Point-of-Sale Solutions Integrate U.are.U(R) Fingerprint Biometrics From DigitalPersona for Quick-Service Restaurants 3DaVitas Patient Centric Modalities Offer Students with Kidney Disease More Choices 56685 1DaVitas Patient Centric Modalities Offer Students with Kidney Disease More Choices 56685 2Childrens Hospital receives federal contract to study antibiotic use in children with UTIs 56680 1Medicine wheel model for nutrition shows promise for control of type 2 diabetes 9854 1Medicine wheel model for nutrition shows promise for control of type 2 diabetes 9854 2
...mal model for the painful nerve condition known as...at it, according to Duke University bioengineers a... but rather a diverse range of symptoms, such as n...adiating leg pain or difficulty in controlling the...ng, of any of the five nerve roots that combine to...
...at Scripps Institution of Oceanography at UC San D...tures below the cobalt blue waters of Lake Tahoe o...ripps research team offer a more comprehensive ana...ion, which suggest a magnitude-7 earthquake occurs... the largest fault in the basin, West Tahoe, appea...
...en using a growing volume of genetic data to debat...to the New World in one wave or successive waves, ... of different populations. , Now, after painstaki...f modern-day Native American and Eurasian groups, ...put the matter to rest: Virtually without exceptio...
Other Biology News:Limping rat provides sciatica insights 2Scripps studies offer new picture of Lake Tahoe's earthquake potential 2Native Americans descended from a single ancestral group, DNA study confirms 2Native Americans descended from a single ancestral group, DNA study confirms 3
... V is a fully integrated system for fluorescent b...that deliver excellent quality microarray images. ...er that is based on patented confocal laser imagin...spatial resolution. The DNAscope V images two fluo...
Rabbit Anti-Ca2+ Channel Ca gamma 2 Polyclonal Antibody, Unconjugated from BD Biosciences Pharmingen
Rabbit Anti-Nuclear Receptor Coactivator 2 (NCOA2) Polyclonal Antibody, Agarose Conjugated from Novus Biologicals
Anti-Monocarboxylate Transporter 2 (MCT2) Polyclonal Antibody, Unconjugated from CHEMICON
Biology Products: